Korea FDA Unveils Initial Biosimilar Guidance; Final Guidelines To Be Released In July
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's FDA is putting the final touches on its EU-modeled initial guidelines for approval and registration of biosimilar products, and anticipates releasing a final version by the end of July